comparemela.com

Latest Breaking News On - Division of lymphoma - Page 1 : comparemela.com

Dr Phillips on the Safety and Efficacy of Glofitamab in Relapsed/Refractory MCL

Tycel Phillips, MD, MPH, discusses updated efficacy and safety data with glofitamab for the treatment of relapsed/refractory mantle cell lymphoma.

Tycel-phillips
Division-of-lymphoma
Department-of-hematology-hematopoietic-cell-transplantation
Hematopoietic-cell-transplantation

City of Hope's Dr Tycel Phillips Discusses Promise of Glofitamab in Heavily Pretreated MCL

Glofitamab is currently being investigated in a phase 1/2, multicenter, open-label, dose-escalation study as monotherapy and in combination with obinutuzumab, following 1-time fixed-dose pretreatment with obinutuzumab.

United-states
American
Tycell-phillips
Department-of-hematology-hematopoietic-cell-transplantation
Division-of-lymphoma
American-society-of-clinical-oncology
American-society
Clinical-oncology
Hematopoietic-cell-transplantation
Chronic-lymphocytic-leukemia

Acalabrutinib Yields Long-Term Efficacy in a Pooled Analysis of Higher-Risk CLL

Treatment with acalabrutinib-based regimens led to long-term benefits in patients with higher-risk CLL, across all lines of therapy.

Massachusetts
United-states
Dana-farber-cancer-institute
Boston
Matthews-davids
Division-of-lymphoma
Harvard-medical-school
Clinical-research
Dana-farber-cancer-institute
Precision-medicine-in-oncology
News

City of Hope Shares Promising Stem Cell and Blood Cancer Data at ASCO 2024

City of Hope Shares Promising Stem Cell and Blood Cancer Data at ASCO 2024
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United-states
Chicago
Illinois
William-dale
Daniel-schmolze
Sumanta-kumar-pal
Tycel-phillips
Marwang-fakih
Richardt-lee
Tanyanika-phillips
Monzrm-al-malki
Cristiane-decat-bergerot

Dr Davids on Treatment With Pirtobrutinib in CLL/SLL With/Without Prior BCL-2 Inhibitor Exposure

Matthew S. Davids, MD, MMSc, discusses key efficacy results from 2 follow-up analyses of the phase 1/2 BRUIN trial evaluating pirtobrutinib.

Matthews-davids
Harvard-medical-school
Division-of-lymphoma
Dana-farber-cancer-institute
Phase-1-2-bruin-trial-nct03740529
Irtobrutinib-jaypirca-
Cll
Usll
Hematologic-malignancies
Richter-transformation

vimarsana © 2020. All Rights Reserved.